The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients
Authors:
- 22 September 2025
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 26 (13-14) , 503-511
Abstract
This study aimed to assess the impact of GSTP1, GSTM1, and GSTT1 polymorphisms on the response to oxaliplatin-based chemotherapy and survival outcomes in gastric cancer patients from Northwest China. Genotypes of GSTP1, GSTM1, and GSTT1 were analyzed in 185 gastric cancer patients receiving SOX/XELOX regimens. The associations of these genotypes with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated through logistic regression and Kaplan-Meier/Cox model analyses. Patients carrying the GSTP1(AG+GG) genotype exhibited a significantly better chemotherapy response (OR = 0.301, p = 0.022) compared to those with the AA genotype. Additionally, the GSTP1 (AG+GG) genotype conferred a reduced risk of disease progression (HR = 1.645, log-rank p = 0.003) and mortality (HR = 1.705, log-rank p = 0.007) relative to the AA genotype. No significant associations were observed for GSTM1 or GSTT1 individually. However, the combined GSTP1(AG+GG)/GSTM1- genotype was linked to an improved chemotherapy response and significantly better overall and progression-free survival. The GSTP1 genotype status could be a valuable predictive biomarker for treatment response and survival, potentially facilitating more personalized therapeutic approaches for gastric cancer.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)Cancer Communications, 2022
- Updates on Management of Gastric CancerCurrent Oncology Reports, 2019
- Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatinGastric Cancer, 2018
- Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivoBiomaterials, 2017
- Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancerClinical and Experimental Medicine, 2017
- GSTM1 and GSTP1 , but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment responseCancer Epidemiology, 2016
- GSTM1, GSTP1, and GSTT1 genetic variability in Turkish and worldwide populationsAmerican Journal of Human Biology, 2014
- Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemiaTumor Biology, 2014
- Variations in glutathione‐S‐transferase genes influence risk of chronic myeloid leukemiaHematological Oncology, 2011
- Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patientsEuropean Journal of Cancer, 2009